These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

841 related items for PubMed ID: 15661240

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Early stage cervical cancer: adjuvant treatment in negative lymph node cases.
    Sartori E, Tisi G, Chiudinelli F, La Face B, Franzini R, Pecorelli S.
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S170-4. PubMed ID: 17765298
    [Abstract] [Full Text] [Related]

  • 23. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation.
    Aoki Y, Sasaki M, Watanabe M, Sato T, Tsuneki I, Aida H, Tanaka K.
    Gynecol Oncol; 2000 May; 77(2):305-9. PubMed ID: 10785483
    [Abstract] [Full Text] [Related]

  • 24. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
    Aoki Y, Watanabe M, Amikura T, Obata H, Sekine M, Yahata T, Fujita K, Tanaka K.
    Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
    [Abstract] [Full Text] [Related]

  • 25. Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery +/- intraoperative electron beam radiotherapy in locally advanced cervical cancer.
    Jurado M, Martínez-Monge R, García-Foncillas J, Azinovic I, Aristu J, López-García G, Brugarolas A.
    Gynecol Oncol; 1999 Jul; 74(1):30-7. PubMed ID: 10385548
    [Abstract] [Full Text] [Related]

  • 26. Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IB-IIA cervical cancer.
    Behtash N, Nazari Z, Ayatollahi H, Modarres M, Ghaemmaghami F, Mousavi A.
    Eur J Surg Oncol; 2006 Dec; 32(10):1226-30. PubMed ID: 16952434
    [Abstract] [Full Text] [Related]

  • 27. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
    Gadducci A, Teti G, Barsotti C, Tana R, Fanucchi A, Orlandini C, Fabrini MG, Genazzani AR.
    Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
    [Abstract] [Full Text] [Related]

  • 28. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
    Lee SH, Lee KC, Choi JH, Oh JH, Baek JH, Park SH, Shin DB.
    Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
    [Abstract] [Full Text] [Related]

  • 29. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.
    Kim YS, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH, Choi EK.
    Gynecol Oncol; 2008 Jan; 108(1):195-200. PubMed ID: 17963825
    [Abstract] [Full Text] [Related]

  • 30. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
    Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG.
    J Clin Oncol; 2004 Mar 01; 22(5):872-80. PubMed ID: 14990643
    [Abstract] [Full Text] [Related]

  • 31. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
    Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, Barakat RR, Alektiar KM.
    Gynecol Oncol; 2013 Feb 01; 128(2):288-93. PubMed ID: 23159818
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Postoperative concurrent daily low-dose cisplatin-based chemoradiation improves the prognosis of patients with pathologic T2b or N1 cervical cancer.
    Mitsuhashi A, Uno T, Usui H, Tate S, Hirashiki K, Kato K, Kiyohara H, Kato S, Ito H, Shozu M.
    Anticancer Res; 2010 Jun 01; 30(6):2341-6. PubMed ID: 20651390
    [Abstract] [Full Text] [Related]

  • 37. Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion.
    Huguet F, Cojocariu OM, Levy P, Lefranc JP, Darai E, Jannet D, Ansquer Y, Lhuillier PE, Benifla JL, Seince N, Touboul E.
    Int J Radiat Oncol Biol Phys; 2008 Dec 01; 72(5):1508-15. PubMed ID: 18676093
    [Abstract] [Full Text] [Related]

  • 38. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy.
    Ho CM, Chien TY, Huang SH, Wu CJ, Shih BY, Chang SC.
    Gynecol Oncol; 2004 May 01; 93(2):458-64. PubMed ID: 15099962
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.